• 1
    Haas S. Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism. Drugs 2004; 64(Suppl 1): 716.
  • 2
    Hyers TM. Management of venous thromboembolism: past, present and future. Arch Intern Med 2003; 163: 75968.
  • 3
    Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Sixth ACCP Consensus Conference on Antithrombotic therapy. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119(Suppl): 8S21S.
  • 4
    Nutescu EA, Helgason CM, Briller J, Schwertz DW. New blood thinner offers first potential alternative in 50 years: ximelagatran. J Cardiovasc Nurs 2004; 19: 37483.
  • 5
    Agnelli G. Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. Drugs 2004; 64(Suppl 1): 4752.
  • 6
    Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Colwell CW. JR. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med, 2002; 137: 64855.
  • 7
    Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, Rathgen K, Svärd R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 55563.
  • 8
    Tanswell P, Koup J. TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program. Int J Clin Pharmacol Ther Toxicol 1993; 31: 51420.
  • 9
    Weitz J. Orally active direct thrombin inhibitors. Sem Cardiovasc Med 2003; 3: 1317.
  • 10
    Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P, Bistro II, Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 10311.
  • 11
    Kher A, Al Dieri R, Hemker HC, Beguin S. Laboratory assessment of antithrombotic therapy: what tests and if so why? Haemostasis 1997; 27: 2118.
  • 12
    Conrad KA. Clinical pharmacology and drug safety: lessons from hirudin. Clin Pharmacol Ther 1995; 58: 1236.
  • 13
    Clarke RJ, Mayo G, Fitzgerald GA, Fitzgerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991; 83: 15108.
  • 14
    Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximegalatran and its active metabolite megalatran: a mini-review. Thromb Res 2003; 109(Suppl 1): S9S15.
  • 15
    Hirsh J. Heparin. N Engl J Med 1991; 324: 156574.
  • 16
    Cullberg M, Eriksson UG, Larsson M, Karlsson MO. Population modelling of the effect of inogatran, a thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease. Br J Clin Pharmacol 2001; 51: 719.
  • 17
    Nowak G. Clinical monitoring of hirudin and direct thrombin inhibitors. Semin Thromb Hemost 2001; 27: 53741.
  • 18
    Carlsson SC, Mattsson C, Eriksson UG, Sarich TC, Wahlander K, Eliasson A, Karlson BW, Sheth SB, Held P. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb Res 2005; 115: 918.
  • 19
    Fenyvesi T, Jorg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 2002; 28: 3618..
  • 20
    Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother 2004; 38: 13838.
  • 21
    Stangier J, Rathgen K, Gansser D, Kohlbrenner V, Stassen JM. Pharmacokinetics of BIBR953ZW, a novel low molecular weight direct thrombin inhibitor in healthy volunteers. Thromb Haemost 2001; (Suppl) Abstract OC2347.